Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2 nd Annual BioConnect Investor Conference, being held in New York, NY.
Management is scheduled to participate in the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35pm ET and will hold one-on-one meetings.
Management is scheduled to participate in the H.C. Wainwright 2 nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 4:00pm ET and will hold one-on-one meetings.
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502567146/en/
Senseonics Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com
